NEW IMPROVED METHOD OF POLYMORPHIC α FORM OF IMATINIB MESYLATE (GLEEVEC®) SYNTHESIS.

Wojciech Łuniewski ,  Wojciech J. Szczepek ,  Łukasz S. Kaczmarek ,  Dorota Samson-Łazińska ,  Bogdan Zagrodzki ,  Teresa Paszkowska-Reymer 

Pharmaceutical Research Institute (IF), Rydygiera 8, Warszawa 01-793, Poland

Abstract

aaa.png

Derivatives of N-phenyl-2-pirimidineamines 2 are valuable intermediates in manufacturing of biologically active compounds. For example, they are used in synthesis of tyrosine kinase inhibitors such as Imatinib, which is approved to treat a rare cancer called Chronic Myeloid Leukemia (CML). On XLVIII Meeting of Polish Chemical Society we revealed improved methods of compound 1 obtaining. Now we would like to show further steps, which lead to polymorphic α form of Gleevec®.
We developed such process conditions, which guaranteed high yields of all synthetics steps as well as simple methods of products' isolation and purification. In our procedure compound 1 is catalytically reduced to amino-derivative using aqueous hydrazine solution. [1] Then compound 2 undergoes reaction with 4-chloromethylbenzoyl chloride in the presence of base, followed by condensation of obtained product 3 with N-methylpiperazine. Resulting reaction mixture is diluted with water or organic solvent chosen from lower aliphatic alcohols or ketones and optionally neutralized with aqueous solution of inorganic base. Precypitated product 4 is then filtered. [2,3] Finally compound 4 free base is converted into methanesulphonic acid salt and crystallized from proper solvent to give desired product in polymorphic form α.[4]

Literatura:
[1] Sposób wytwarzania N-(5-amino-2-metylofenylo)-4-(3-pirydylo)-2-pirymidynoaminy P-377984
[2] Sposób wytwarzania pochodnych N-fenylo-2-pirymidynoamin P-376691
[3] Process for preparation of imatinib base PCT/PL/2005/000088
[4] Process for preparation of imatinib monomesylate crystalline Form α PCT/PL2005/000024

Legal notice
  • Legal notice:

    Copyrighted materials, (c) Pielaszek Research, all rights reserved.
    The above materials, including auxiliary resources, are subject to Publisher's copyright and the Author(s) intellectual rights. Without limiting Author(s) rights under respective Copyright Transfer Agreement, no part of the above documents may be reproduced, stored in or introduced into a retrieval or caching system, or transmitted in any form or by any means (electronic, mechanical, photocopying, recording or otherwise), or for any purpose, without the express written permission of Pielaszek Research, the Publisher. Express permission from the Author(s) is required to use the above materials for academic purposes, such as lectures or scientific presentations.
    In every case, proper references including Author(s) name(s) and URL of this webpage: http://science24.com/paper/6442 must be provided.

 

Related papers
  1. The comparison of the stability indicating  two HPLC methods and their application for the determination of bosentan in coated tablets 
  2. Application of the new data processing method for photodiode array detector in the analysis of drug substances
  3. Improved manufacturing process of bosentan monohydrate.
  4. Development and validation of the GC method for quantitative determination of semi-volatile solvents in pharmaceutical substance Bosentan
  5. Characterization of dutasteride polymorphic forms
  6. Comparison of ultraviolet detection and charged aerosol detection methods for liquid-chromatographic determination of protoescigenin
  7. An application of accelerator mass spectrometry (AMS) in pediatric clinical studies. Paracetamol, midazolam and spironolactone radiosynthesis and certification.
  8. Synthesis of potential impurities of loteprednol etabonate and methods for chemical purity determination
  9. Assessment of selected synthesis of bosentan towards elimination of known impurities.
  10. Development and validation of the HPLC-UV method for impurities determination in duloxetine hydrochloride
  11. An improved process for the preparation of 2-amino-N-tert-butyl-2-cyanoamide hydrochlorie.
  12. Distinguishing between polymorphic forms of linezolid by solid-phase electronic and vibrational circular dichroism
  13. Preparation of protoaescigenin from escin.
  14. Synthesis and biological evaluation of new amino acid and dipeptide derivatives of neocryptolepine as anticancer agents. 
  15. Analytical control of synthesis and determination of BR-S by HPLC
  16. Opimisation of preparation of TZ-6
  17. HPLC method as an analitycal control of synthesis and determination of TZ-S
  18. Direct enantiomeric resolution of tamsulosin, clinically used chiral O-phenylethanolamine derivative with α1-blocking activity
  19. Investigation of unknown impurity of TD-S by HPLC-MS
  20. Validation of a HPLC method for LI-S analysis
  21. New amino acid and peptide derivatives of 5H-indolo[2,3-b]quinoline and their biological activity.
  22. The Concept of the Central Strategic Program - Innovative Medicines
  23. The evaluation of tolterodine tartrate synthesis based on patent EP 0 325 574 B1.
  24. Zolmitriptan synthesis and in-process control by HPLC methods
  25. The cytotoxic activity of glycosides of indolo[2,3-b]quinoline derivatives.
  26. Disubstituted indolo[2,3-b]quinoline derivatives - the cytotoxic activity in vitro against various human tumor cell lines.
  27. Mono substituted 5H- and 6H-indolo[2,3-b]quinoline derivatives and their ability to overcome the barrier of drug resistance.
  28. Synthesis of selected 14C radiolabelled compounds in recent investigations of new analytical method applied in accelerated drug development (EUMAPP).
  29. HPLC as a method for analytical control of synthesis and determination of tolterodine (TD-S)
  30. The Crystal Structure of distrontium salt of 5-[bis(carboxymethyl)amino]-3-carboxymethyl-4-cyano-2-thiophenecarboxylic acid
  31. Optimization of AR-3 synthesis
  32. New amino acid derivatives of 6H-indolo[2,3-b]quinolines
  33. Polimorphism of Active Pharmaceutical Ingredients
  34. CAN A QUEST FOR A NEW DRUG OF POLISH ORIGIN BE SUCCESSFUL?
  35. ROPINIROL - GENERIC DRUG FOR PARKINSON'S DISEASE
  36. QUINONES AND HYDROQUINONES SEPARATION AND DETERMINATION BY HPLC CHROMATOGRAPHY
  37. CHARACTERIZATION OF ARIPIPRAZOLE SOLVATE WITH ETHANOL AND POLYMORPHIC FORMS PRODUCED DURING ITS HEATING
  38. OPTIMIZATION OF THE CHROMATOGRAPHIC SEPARATION BY HPLC METHOD AND CONFIRMATION OF THE IDENTITY OF CHOSEN ESCITALOPRAM OXALATE INTERMEDIATE PRODUCTS
  39. GC METHOD FOR QUANTITATIVE DETER- MINATION OF RESIDUAL 2-(2-CHLORO- ETOXY)ETHANOL (CEE) AND N-METHYL- 2-PYRROLIDINONE (NMP) IN PHARMACEU- TICAL ACTIVE SUBSTANCE
  40. THE CYTOTOXIC GLYCOSIDES OF INDOLO[2,3-B]QUINOLINE DERIVATIVES. IN VITRO AND IN VIVO STUDIES
  41. MONO SUBSTITUTED 5H-INDOLO[2,3-B]- QUINOLINE DERIVATIVES AND THEIR ABILITY TO OVERCOME THE BARRIER OF DRUG RESISTANCE.
  42. DISUBSTITUTED INDOLO[2,3-b]QUINOLINE DERIVATIVES. THE CYTOTOXIC ACTIVITY IN VITRO AGAINST VARIOUS HUMAN TUMOR CELL LINE.
  43. SYNTHESIS OF PIOGLITAZONE HYDROCHLORIDE OF PHARMACEUTICAL PURITY AT SMALL PLANT SCALE
  44. 1H AND 13C NMR DATA FOR INDOLO[2,3-b]QUINOLINES - AMINOGLYCOSIDE HYBRIDS, A NOVEL POTENT ANTICANCER DRUG FAMILY .
  45. NEW SYNTHESIS OF 11-(1-PIPERAZINYL)- DIBENZO[b,f][1,4]THIAZEPINE, A CRUCIAL INTERMEDIATE IN QUETIAPINE PRODUCTION.

Presentation: Poster at V Multidyscyplinarna Konferencja Nauki o Leku, by Wojciech Łuniewski
See On-line Journal of V Multidyscyplinarna Konferencja Nauki o Leku

Submitted: 2006-01-26 16:18
Revised:   2009-06-07 00:44
Google
 
Web science24.com
© 1998-2021 pielaszek research, all rights reserved Powered by the Conference Engine